Synergetic immunotherapies and current molecular targets in oral cancer treatment
The development of cancer therapies depends on identifying exploitable differences between the host immune response and the tumorigenicity. These include anatomic, metabolic, cell cycle kinetics, and presumed antigenic differences between the normal tissue and tumor cells. Immunotherapy also called...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2017-01-01
|
| Series: | Journal of Dr. NTR University of Health Sciences |
| Subjects: | |
| Online Access: | http://www.jdrntruhs.org/article.asp?issn=2277-8632;year=2017;volume=6;issue=2;spage=73;epage=81;aulast=Nalabolu |
| _version_ | 1818280184979128320 |
|---|---|
| author | Govind Raj K Nalabolu N Pallavi Santhosh Kumar S Hiremath Smita S Birajdar |
| author_facet | Govind Raj K Nalabolu N Pallavi Santhosh Kumar S Hiremath Smita S Birajdar |
| author_sort | Govind Raj K Nalabolu |
| collection | DOAJ |
| description | The development of cancer therapies depends on identifying exploitable differences between the host immune response and the tumorigenicity. These include anatomic, metabolic, cell cycle kinetics, and presumed antigenic differences between the normal tissue and tumor cells. Immunotherapy also called biologic therapy is a treatment that uses body's own immune system to fight against cancer. Cells such as dendritic cells (DCs), natural killer cells, effector T-cells, and molecules such as complement can be used in various treatment modalities which are segregated as “active” and “passive” based on their ability to engage the host immune system. Further both active and passive immunotherapies can be subdivided into specific and nonspecific approaches. Thus, it is essential to understand the therapeutic approaches and the vaccines made based on the role played by these cells and molecules to circumvent the barriers of tumor microenvironment for an antitumor response. Hence, through this article efforts were made to comprehensively explain the concepts of cancer vaccines and immunotherapies in the treatment of oral cancer. |
| first_indexed | 2024-12-12T23:45:12Z |
| format | Article |
| id | doaj.art-69be31b566964eafbe81a6c743611528 |
| institution | Directory Open Access Journal |
| issn | 2277-8632 |
| language | English |
| last_indexed | 2024-12-12T23:45:12Z |
| publishDate | 2017-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Dr. NTR University of Health Sciences |
| spelling | doaj.art-69be31b566964eafbe81a6c7436115282022-12-22T00:06:52ZengWolters Kluwer Medknow PublicationsJournal of Dr. NTR University of Health Sciences2277-86322017-01-0162738110.4103/JDRNTRUHS.JDRNTRUHS_6_17Synergetic immunotherapies and current molecular targets in oral cancer treatmentGovind Raj K NalaboluN PallaviSanthosh Kumar S HiremathSmita S BirajdarThe development of cancer therapies depends on identifying exploitable differences between the host immune response and the tumorigenicity. These include anatomic, metabolic, cell cycle kinetics, and presumed antigenic differences between the normal tissue and tumor cells. Immunotherapy also called biologic therapy is a treatment that uses body's own immune system to fight against cancer. Cells such as dendritic cells (DCs), natural killer cells, effector T-cells, and molecules such as complement can be used in various treatment modalities which are segregated as “active” and “passive” based on their ability to engage the host immune system. Further both active and passive immunotherapies can be subdivided into specific and nonspecific approaches. Thus, it is essential to understand the therapeutic approaches and the vaccines made based on the role played by these cells and molecules to circumvent the barriers of tumor microenvironment for an antitumor response. Hence, through this article efforts were made to comprehensively explain the concepts of cancer vaccines and immunotherapies in the treatment of oral cancer.http://www.jdrntruhs.org/article.asp?issn=2277-8632;year=2017;volume=6;issue=2;spage=73;epage=81;aulast=NalaboluAdoptive cell therapycancer vaccinecomplementsdendritic cellsimmunotherapynatural killer cellsoral cancertumor-targeted monoclonal antibodiestumor microenvironment |
| spellingShingle | Govind Raj K Nalabolu N Pallavi Santhosh Kumar S Hiremath Smita S Birajdar Synergetic immunotherapies and current molecular targets in oral cancer treatment Journal of Dr. NTR University of Health Sciences Adoptive cell therapy cancer vaccine complements dendritic cells immunotherapy natural killer cells oral cancer tumor-targeted monoclonal antibodies tumor microenvironment |
| title | Synergetic immunotherapies and current molecular targets in oral cancer treatment |
| title_full | Synergetic immunotherapies and current molecular targets in oral cancer treatment |
| title_fullStr | Synergetic immunotherapies and current molecular targets in oral cancer treatment |
| title_full_unstemmed | Synergetic immunotherapies and current molecular targets in oral cancer treatment |
| title_short | Synergetic immunotherapies and current molecular targets in oral cancer treatment |
| title_sort | synergetic immunotherapies and current molecular targets in oral cancer treatment |
| topic | Adoptive cell therapy cancer vaccine complements dendritic cells immunotherapy natural killer cells oral cancer tumor-targeted monoclonal antibodies tumor microenvironment |
| url | http://www.jdrntruhs.org/article.asp?issn=2277-8632;year=2017;volume=6;issue=2;spage=73;epage=81;aulast=Nalabolu |
| work_keys_str_mv | AT govindrajknalabolu synergeticimmunotherapiesandcurrentmoleculartargetsinoralcancertreatment AT npallavi synergeticimmunotherapiesandcurrentmoleculartargetsinoralcancertreatment AT santhoshkumarshiremath synergeticimmunotherapiesandcurrentmoleculartargetsinoralcancertreatment AT smitasbirajdar synergeticimmunotherapiesandcurrentmoleculartargetsinoralcancertreatment |